Generex Given GoAhead to Proceed With Study of Triple Negative Breast Cancer Treatment

Generex Given Go-Ahead to Proceed With Study of Triple Negative Breast Cancer Treatment

16:45 EST 12 Dec 2018 | R&D Magazine

News
The combination study builds on previous clinical studies of both cancer vaccine AE37 and Keytruda.
Contributed Author: 
Generex Biotechnology Corporation
Topics: 
Oncology

More From BioPortfolio on "Generex Given Go-Ahead to Proceed With Study of Triple Negative Breast Cancer Treatment"